Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Donohue MC, Gamst AC, Aisen PS.

Alzheimers Dement. 2011 Mar;7(2):245-6; author reply 247-9. doi: 10.1016/j.jalz.2010.12.013. No abstract available.

PMID:
21414558
2.

Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Schneider LS, Kennedy RE, Cutter GR; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 Sep;6(5):367-77. doi: 10.1016/j.jalz.2010.07.004.

3.

Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?

Zetterberg H.

Recent Pat CNS Drug Discov. 2008 Jun;3(2):109-11. Review.

PMID:
18537770
4.

Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment.

Forlenza OV, Diniz BS, Talib LL, Radanovic M, Yassuda MS, Ojopi EB, Gattaz WF.

Rev Bras Psiquiatr. 2010 Sep;32(3):216-22. Epub 2010 Apr 16.

5.

Biomarker profiles and their relation to clinical variables in mild cognitive impairment.

Schoonenboom SN, Visser PJ, Mulder C, Lindeboom J, Van Elk EJ, Van Kamp GJ, Scheltens PH.

Neurocase. 2005 Feb;11(1):8-13.

PMID:
15804919
7.

Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.

Dean RA, Shaw LM.

Clin Chem. 2010 Jan;56(1):7-9. doi: 10.1373/clinchem.2009.134692. Epub 2009 Nov 19. No abstract available.

8.

Alzheimer's CSF markers in older schizophrenia patients.

Frisoni GB, Prestia A, Geroldi C, Adorni A, Ghidoni R, Amicucci G, Bonetti M, Soricelli A, Rasser PE, Thompson PM, Giannakopoulos P.

Int J Geriatr Psychiatry. 2011 Jun;26(6):640-8. doi: 10.1002/gps.2575. Epub 2010 Sep 27.

PMID:
20872913
9.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
10.

Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.

Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blankenstein MA.

Neurobiol Aging. 2010 Apr;31(4):539-40; author reply 541. doi: 10.1016/j.neurobiolaging.2008.07.024. Epub 2008 Oct 28. No abstract available.

PMID:
18963255
11.

Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.

de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, Dubois B, Sarazin M.

J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):240-6. doi: 10.1136/jnnp.2010.207183. Epub 2010 Aug 27.

12.

Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.

Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H.

Brain. 2008 May;131(Pt 5):1252-8. doi: 10.1093/brain/awn034. Epub 2008 Mar 11.

PMID:
18334538
13.

Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.

Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.

Mech Ageing Dev. 2006 Feb;127(2):129-32. Epub 2005 Nov 7.

PMID:
16274728
14.

Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory.

Dumurgier J, Paquet C, Benisty S, Kiffel C, Lidy C, Mouton-Liger F, Chabriat H, Laplanche JL, Hugon J.

Neurobiol Dis. 2010 Nov;40(2):456-9. doi: 10.1016/j.nbd.2010.07.007. Epub 2010 Jul 22.

PMID:
20656030
15.

Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.

Rami L, Fortea J, Bosch B, Solé-Padullés C, Lladó A, Iranzo A, Sánchez-Valle R, Molinuevo JL.

J Alzheimers Dis. 2011;23(2):319-26. doi: 10.3233/JAD-2010-101422.

PMID:
21098971
16.

Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?

Mitchell AJ, Monge-Argilés JA, Sánchez-Paya J.

Pract Neurol. 2010 Aug;10(4):202-7. doi: 10.1136/jnnp.2010.217778. Review.

PMID:
20647526
17.

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K.

Dement Geriatr Cogn Disord. 2007;23(5):316-20. Epub 2007 Mar 19.

PMID:
17374949
18.

CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.

Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.

J Neurol Sci. 2006 Dec 21;251(1-2):124-8. Epub 2006 Nov 9.

PMID:
17097109
19.

Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease.

Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M, Ramirez MJ, Cedazo-Mínguez A.

J Alzheimers Dis. 2010;22(2):405-13. doi: 10.3233/JAD-2010-100795.

PMID:
20847404
20.

Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.

van Rossum IA, Vos S, Handels R, Visser PJ.

J Alzheimers Dis. 2010;20(3):881-91. doi: 10.3233/JAD-2010-091606. Review.

PMID:
20413876

Supplemental Content

Support Center